(NYSEMKT: OSTX) Os Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.12%.
Os Therapies's earnings in 2026 is -$28,753,844.On average, 7 Wall Street analysts forecast OSTX's earnings for 2026 to be -$25,000,813, with the lowest OSTX earnings forecast at -$30,606,624, and the highest OSTX earnings forecast at -$18,679,450. On average, 6 Wall Street analysts forecast OSTX's earnings for 2027 to be -$5,376,519, with the lowest OSTX earnings forecast at -$6,973,661, and the highest OSTX earnings forecast at -$2,905,692.
In 2028, OSTX is forecast to generate $1,814,575 in earnings, with the lowest earnings forecast at -$6,973,661 and the highest earnings forecast at $11,207,670.